ARCHIVES

Zometa Can Reduce Risk Of Skeletal-Related Events

This article is from The Cancer Letter archive.

Vol. 34 No. 8 | August 26, 2011

Download PDF Visit The Full Archive

Related Articles

Motesanib Does Not Improve OS; Study Doesn’t Meet Primary Endpoint

April 29, 2011

Organ Systems R01 Grants Doing Okay

February 8, 1985

Appropriations: NIH Professional Needs Budget Gains Attention

March 14, 1997

Cancer Center Directors to Develop Blueprint for Progress That’s “Honest,” M.D. Anderson’s John Mendelsohn Says.

November 22, 2006

NCI Awards Regional CIS Contracts

August 6, 1993

Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months

September 27, 2013